公开(公告)号：US20150126401A1

公开(公告)日：2015-05-07

申请号：US14598630

申请日：2015-01-16

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Norbert Wild ,  Ursula Garczarek

IPC: G01N33/574

CPC classification number: G01N33/57419 ,  G01N33/721 ,  G01N2333/4727 ,  G01N2333/805

Abstract: The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of the hemoglobin/haptoglobin complex and calprotectin and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer based on a method of this invention the level of one or more additional marker may be determined together with the hemoglobin/haptoglobin complex and calprotectin in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising the hemoglobin/haptoglobin complex and calprotectin in the early diagnosis of colorectal cancer and it teaches a kit for performing the method of the invention.

Abstract translation: 本发明涉及一种协助评估结肠直肠癌的方法。 该方法特别用于评估体外存在或不存在结肠直肠癌。 该方法例如通过分析生物化学标记来实施，包括在粪便样品中测量血红蛋白/触珠蛋白复合物和钙卫蛋白的浓度，并将确定的浓度与不存在或存在结肠直肠癌相关联。 为了进一步改进基于本发明方法的结肠直肠癌的评估，可以在粪便样品中与血红蛋白/触珠蛋白复合物和钙卫蛋白一起测定一种或多种另外的标记物的水平，并与结肠直肠癌的存在或不存在相关 。 本发明还涉及包含血红蛋白/触珠蛋白复合物和钙卫蛋白的标记物在早期诊断结肠直肠癌中的用途，并且其教导了用于实施本发明方法的试剂盒。

公开(公告)号：US20170115294A1

公开(公告)日：2017-04-27

申请号：US15399801

申请日：2017-01-06

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Norbert Wild ,  Ursula Garczarek ,  Andrea Geistanger ,  Herbert Andres ,  Marie-Luise Hagmann ,  Johann Karl ,  Freidemann Krause ,  Michael Pfeffer ,  Wolfgang Rollinger ,  Michael Tacke ,  Michael Thierolf

IPC: G01N33/574

CPC classification number: G01N33/57419 ,  C12Q1/6886 ,  G01N2333/4727 ,  G01N2333/805 ,  G01N2333/8146 ,  G01N2333/9121

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

公开(公告)号：US20150192587A1

公开(公告)日：2015-07-09

申请号：US14463975

申请日：2014-08-20

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Norbert Wild ,  Ursula Garczarek ,  Andrea Geistanger ,  Herbert Andres ,  Marie-Luise Hagmann ,  Johann Karl ,  Friedemann Krause ,  Michael Pfeffer ,  Wolfgang Rollinger ,  Michael Tacke ,  Michael Thierolf

IPC: G01N33/574

CPC classification number: G01N33/57419 ,  C12Q1/6886 ,  G01N2333/4727 ,  G01N2333/805 ,  G01N2333/8146 ,  G01N2333/9121

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.